Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965504 | 0.83 | MCL1 (0.74) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL9965507 | 0.82 | MCL1 (0.70) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL30783048 | 0.82 | MCL1 (0.70) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL23854804 | 0.81 | HSP90AA1 (0.84) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL15783182 | 0.80 | MCL1 (0.70) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL9965753 | 0.80 | MCL1 (0.70) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL15783245 | 0.79 | MCL1 (0.76) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL15783261 | 0.79 | MCL1 (0.72) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL30783045 | 0.79 | MCL1 (0.65) | MCL1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL27379922 | 0.79 | MCL1 (0.65) | MCL1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | MCL1 1/4885MAPT 4595/4885MEN1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.